ArticleNucleic acids research2009
Identification of HCV protease inhibitor resistance mutations by selection pressure-based method.
Article in Nucleic acids research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.Antimicrobial agents and chemotherapy · 2012Trial
- Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.Journal of gastroenterology · 2011Trial
- Major mutations in the NS3 gene region of hepatitis C virus related to the resistance to direct acting antiviral drugs: a systematic review.Virusdisease · 2020Review
- Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism.World journal of hepatology · 2014Review
- Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strains.PloS one · 2014Article
- Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.Journal of clinical microbiology · 2013Article
- Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors.Memorias do Instituto Oswaldo Cruz · 2013Article
- HCV IRES-mediated core expression in zebrafish.PloS one · 2013Article
- Article
- Analysis of hepatitis C virus intrahost diversity across the coding region by ultradeep pyrosequencing.Journal of virology · 2012Article
- Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease.Antimicrobial agents and chemotherapy · 2012Article
- Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.Journal of viral hepatitis · 2012Article
- Antioxidant and antiviral activities of lipophilic epigallocatechin gallate (EGCG) derivatives.Journal of functional foods · 2012Article
- HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors.PloS one · 2012Article
- Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions.Genetics and molecular biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major challenge to successful antiviral therapy is the emergence of drug-resistant viruses. Recent studies have developed several automated analyses of HIV sequence polymorphism based on calculations of selection pressure (K(a)/K(s)) to predict drug resistance mutations. Similar resistance analysis programs for HCV inhibitors are not currently available. Taking advantage of the recently available sequence data of patient HCV samples from a Phase II clinical study of protease inhibitor boceprevir, we calculated the selection pressure for all codons in the HCV protease region (amino acid 1-181) to identify potential resistance mutations. The correlation between mutations was also calculated to evaluate linkage between any two mutations. Using this approach, we identified previously known major resistant mutations, including a recently reported mutation V55A. In addition, a novel mutation V158I was identified, and we further confirmed its resistance to boceprevir in protease enzyme and replicon assay. We also extended the approach to analyze potential interactions between individual mutations and identified three pairs of correlated changes. Our data suggests that selection pressure-based analysis and correlation mapping could provide useful tools to analyze large amount of sequencing data from clinical samples and to identify new drug resistance mutations as well as their linkage and correlations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.